World Hepatitis Day, 28th July 2014
28th July marks World Hepatitis Day, a drive to increase the awareness and understanding of viral hepatitis and marks an opportunity to think about how we can influence change for better.
28th July marks World Hepatitis Day, a drive to increase the awareness and understanding of viral hepatitis and marks an opportunity to think about how we can influence change for better. The ‘Think Again’ campaign encourages people to challenge our perceptions of hepatitis, and aims to get people thinking again about what they think they know (or don’t know) about the disease. As part of this we have been encouraged to send in pictures which have challenged us to think again about the world we live in, and what we can do to help spread the word about hepatitis.
One thing that grasps my interest is how society has adopted military style language when talking about cancer
Treatments are described as “defending” or “protecting” whilst cancer patients themselves are “fighters” who “battle” to “beat” the disease. These abstract metaphors of war are used in an attempt to articulate that cancer is a very emotional experience for all involved.
This terminology is intriguing to me, as whilst widely recognised as persuasive, it is also considered controversial. War-like analogies suggest that there will be a “winner”, “loser”, and a “battlefield”. Sadly there are hundreds of types of cancer, and short of resection, there is no definitive cure for any of them. I have to ask myself, how do progressed metastatic patients feel anything other than failure when we talk about the disease in this way?
Therapy Watch HCV expands into new LATAM markets
The HCV market has been growing and changing remarkably quickly over the last 5 years, and public awareness and increased testing have led to a massive increase in the number of patients presenting for treatment.
To date there have been 4 new drugs launched, and there are more in all stages of development; with these advances in drug therapy come better patient outcomes and length of time on treatment has come down from an average of six months to 12 weeks - making it much easier for the patient to achieve SVR.
EphMRA Annual Conference 2014
Embracing change and cultivation opportunity
Research Partnership was delighted to exhibit at the annual event. We were pleased to be able to offer delegates our latest Free Thinking white papers, “Biosimilars: Friend or foe to healthcare” which looks at the opportunities for biosimilars and the threats to innovator biologics, and ‘Excellence in Oncology’ which considers what information manufacturers need in order to develop an effective biomarker strategy. In addition delegates were able to discover the latest in our mobile research capabilities, including our unique approach to conference evaluation, the new developments we have made to our real-time patient audit tracking tool Therapy Watch and pick up our free emerging markets top tip guides to conducting effective research in the BRIC markets.
An overview of the six most-commonly researched, largest pharmaceutical markets in ASEAN